IDEXX Laboratories Analysts Cut Their Forecasts Following Q4 Results

Core Viewpoint - IDEXX Laboratories Inc. reported strong fourth-quarter financial results for 2025, exceeding expectations, and provided a positive forecast for fiscal 2026 [1][2][3] Financial Performance - Fourth-quarter 2025 earnings were $3.08 per share, an 18% increase year over year, surpassing the consensus estimate of $2.94 [1] - Sales for the fourth quarter reached $1.091 billion, exceeding the consensus of $1.073 billion, reflecting a 14% increase on a reported basis and a 12% increase on an organic basis [1] Fiscal 2026 Forecast - IDEXX Laboratories expects earnings for fiscal 2026 to be in the range of $14.29 to $14.80 per share, compared to the consensus estimate of $14.39 [2] - The company forecasts annual sales for 2026 to be between $4.632 billion and $4.720 billion, above the consensus of $4.658 billion, driven by CAG Diagnostics recurring revenue growth of 8.6% to 10.6% as reported and 8.0% to 10.0% on an organic basis [3] Market Reaction - Following the earnings announcement, IDEXX Laboratories shares increased by 1.7%, trading at $650.54 [3] Analyst Ratings - BTIG analyst Mark Massaro maintained a Buy rating on IDEXX Laboratories but lowered the price target from $830 to $800 [4] - UBS analyst Andrea Alfonso maintained a Neutral rating and reduced the price target from $750 to $730 [4]